### USER
As a busy physician, I already have a comprehensive guidance document for the attached material. I’ve included the full guidance for reference.

Could you please condense this lengthy document into a one-page reference algorithm for fast memory aide and fast decision making? This will allow me to quickly access key points during patient consultations.

### ASSISTANT
Certainly. Below is a **condensed one-page reference algorithm** based on the NICE CKS guidance for **HIV infection and AIDS**, designed for rapid recall and clinical decision-making in primary care.

---

### **HIV Infection & AIDS: One-Page Clinical Algorithm**  
*Based on NICE CKS (March 2025)*

---

#### **1. WHEN TO SUSPECT HIV**  
Consider HIV testing in individuals with:  
- **Persistent generalized lymphadenopathy**  
- **Unexplained weight loss, fever, night sweats, or diarrhea**  
- **Recurrent infections** (e.g., shingles, oral thrush, bacterial pneumonia)  
- **Opportunistic infections or AIDS-defining conditions**  
- **Sexual health concerns**, STIs, or high-risk sexual behavior  
- **History of injecting drug use**, incarceration, or migration from high-prevalence country (>1% adult HIV prevalence)  
- **Pregnancy** (routine offer of testing)  
- **Partner known to be HIV-positive**

> **"Think HIV"** in any unexplained illness or risk factor.

---

#### **2. TESTING & DIAGNOSIS**  
- **Test**: 4th generation HIV p24 antigen/antibody combination immunoassay (blood).  
- **Rapid point-of-care tests** acceptable if followed by lab confirmation.  
- **Reactive test → Confirm** with:  
  - Differentiation assay (to distinguish HIV-1/2)  
  - Viral load and CD4 count (urgent if symptomatic)  
- **Diagnosis confirmed** when:  
  - Positive immunoassay + positive differentiation assay  
  - Or positive virological test (e.g., RNA PCR)  

> **Do not delay referral** after preliminary positive.

---

#### **3. IMMEDIATE ACTIONS AFTER DIAGNOSIS**  
✅ **Refer urgently** (within 7 days) to specialist HIV service.  
✅ **Initiate discussion on**:  
  - Transmission risks and prevention  
  - Partner notification (offer support)  
  - Mental health, social support, and disclosure  
  - Importance of ART adherence  
✅ **Avoid starting ART in primary care** – manage by specialists.

---

#### **4. SCREENING RECOMMENDATIONS**  
Offer **opt-out HIV testing** to:  
- All patients in **high-prevalence areas** (diagnosis rate >2/1000)  
- **Pregnant women** (routine antenatal screening)  
- **Anyone with HIV risk factor(s)**  
- **Individuals attending sexual health, drug services, or TB clinics**

> Repeat testing annually in ongoing risk.

---

#### **5. ACUTE HIV (SEROCONVERSION ILLNESS)**  
Suspect in:  
- Flu-like illness (fever, rash, pharyngitis, myalgia) 2–6 weeks post-exposure  
- Negative or indeterminate test but high clinical suspicion → **test HIV RNA (PCR)**

> **Urgent referral** – early ART may improve outcomes.

---

#### **6. WHEN TO REFER OR ADMIT**  
**Refer urgently (same day)** if:  
- Suspected **acute HIV with severe symptoms**  
- **Opportunistic infection** (e.g., PCP, toxoplasmosis, cryptococcal meningitis)  
- **Severe immune suppression** (CD4 <200 cells/µL)  
- **AIDS-defining illness** (e.g., Kaposi’s sarcoma, CNS lymphoma)  
- **ART toxicity or treatment failure**

**Admit if**:  
- Hemodynamically unstable  
- Severe infection (e.g., PJP pneumonia, sepsis)  
- Neurological compromise

---

#### **7. POST-EXPOSURE PROPHYLAXIS (PEP)**  
**Consider PEP if**:  
- Recent (≤72 hrs) **high-risk exposure** (e.g., condomless sex with HIV+ partner, needle-stick injury)  
- Source likely **HIV-positive or unknown status with risk**

> **Act fast**:  
> - Start PEP **within 72 hours** (sooner = better)  
> - Prescribe **28-day regimen** (e.g., tenofovir/emtricitabine + dolutegravir)  
> - **Refer to sexual health or A&E** for assessment and PEP initiation

> **Do not delay** – PEP is time-critical.

---

#### **8. LONG-TERM MANAGEMENT IN PRIMARY CARE**  
Support includes:  
- **Monitoring** for cardiovascular, renal, hepatic, and bone disease  
- **Vaccinations**: Annual flu, pneumococcal, HPV, hepatitis A/B  
- **Mental health screening** (depression, anxiety)  
- **Sexual & reproductive health** (including safe conception)  
- **Smoking cessation, alcohol, and lifestyle advice**  
- **Palliative care input** when needed (advanced disease)

> **Collaborate** with HIV team – shared care possible.

---

#### **9. KEY POINTS**  
- **Early diagnosis saves lives** – maintain low threshold for testing.  
- **All positives require urgent specialist referral**.  
- **PEP must start ≤72 hours post-exposure**.  
- **Undetectable = Untransmittable (U=U)** – reinforce with patients.  
- **No cure, but ART enables near-normal life expectancy**.

---

*References: NICE CKS – HIV Infection and AIDS (Mar 2025), BHIVA, BASHH, WHO*  
*© Clarity Informatics Ltd (trading as Agilio Software Primary Care). Used under licence from NICE.*

--- 

This algorithm can be printed and kept as a quick-reference tool. Let me know if you’d like a version formatted for wallet card or EMR integration.

### USER
Design an attractive HTML/CSS webpage with a clean, modern UI that displays all the provided information in a visually appealing layout.

### ASSISTANT
```html
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
  <title>NICE CKS: HIV Infection & AIDS - Clinical Guidance</title>
  <link href="https://fonts.googleapis.com/css2?family=Roboto:wght@300;400;500;700&display=swap" rel="stylesheet">
  <style>
    * {
      margin: 0;
      padding: 0;
      box-sizing: border-box;
    }

    body {
      font-family: 'Roboto', sans-serif;
      background-color: #f8f9fa;
      color: #333;
      line-height: 1.6;
    }

    .container {
      max-width: 1000px;
      margin: 30px auto;
      padding: 20px;
      background: white;
      border-radius: 12px;
      box-shadow: 0 6px 20px rgba(0, 0, 0, 0.1);
    }

    header {
      text-align: center;
      margin-bottom: 30px;
      padding-bottom: 20px;
      border-bottom: 1px solid #eaeaea;
    }

    header h1 {
      font-size: 28px;
      font-weight: 700;
      color: #1a539d;
    }

    header p {
      font-size: 16px;
      color: #555;
      margin-top: 8px;
    }

    .revision {
      font-size: 14px;
      color: #777;
      font-style: italic;
    }

    .section {
      margin-bottom: 30px;
      padding: 20px;
      background: #f5f9ff;
      border-left: 5px solid #1a539d;
      border-radius: 8px;
    }

    .section h2 {
      font-size: 20px;
      color: #1a539d;
      margin-bottom: 15px;
      font-weight: 500;
    }

    .section ul {
      list-style-type: none;
      padding-left: 10px;
    }

    .section ul li {
      margin-bottom: 10px;
      padding-left: 20px;
      position: relative;
    }

    .section ul li::before {
      content: "•";
      color: #1a539d;
      font-weight: bold;
      position: absolute;
      left: 0;
    }

    .card-grid {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
      gap: 20px;
      margin-top: 20px;
    }

    .card {
      background: white;
      padding: 18px;
      border-radius: 10px;
      box-shadow: 0 4px 10px rgba(0, 0, 0, 0.05);
      border: 1px solid #e0e7ff;
    }

    .card h3 {
      font-size: 18px;
      color: #1a539d;
      margin-bottom: 12px;
      font-weight: 500;
    }

    .card ul {
      list-style: none;
    }

    .card ul li::before {
      content: "→";
      color: #1a539d;
      margin-right: 8px;
    }

    .highlight-box {
      background: #e8f4fc;
      padding: 16px;
      border-radius: 8px;
      border-left: 5px solid #007acc;
      margin: 20px 0;
      font-size: 15px;
    }

    .footer {
      text-align: center;
      margin-top: 40px;
      font-size: 13px;
      color: #888;
      padding-top: 20px;
      border-top: 1px solid #eee;
    }

    .footer p {
      margin: 5px 0;
    }
  </style>
</head>
<body>
  <div class="container">
    <header>
      <h1>HIV Infection and AIDS: Clinical Guidance</h1>
      <p>Condensed reference for healthcare professionals based on NICE CKS</p>
      <p class="revision">Last revised: March 2025</p>
    </header>

    <div class="section">
      <h2>When to Suspect HIV</h2>
      <ul>
        <li>Persistent generalized lymphadenopathy</li>
        <li>Unexplained weight loss, fever, night sweats, or diarrhea</li>
        <li>Recurrent infections (e.g., shingles, oral thrush, bacterial pneumonia)</li>
        <li>Opportunistic infections or AIDS-defining conditions</li>
        <li>Sexual health concerns, STIs, or high-risk sexual behavior</li>
        <li>History of injecting drug use, incarceration, or migration from high-prevalence country (>1% adult HIV prevalence)</li>
        <li>Pregnancy (routine offer of testing)</li>
        <li>Partner known to be HIV-positive</li>
      </ul>
    </div>

    <div class="section">
      <h2>Diagnosis</h2>
      <ul>
        <li><strong>Test:</strong> 4th generation HIV p24 antigen/antibody combination immunoassay (blood)</li>
        <li>Rapid point-of-care tests acceptable if followed by lab confirmation</li>
        <li><strong>Reactive test → Confirm</strong> with differentiation assay (HIV-1/2) and viral load/CD4</li>
        <li><strong>Diagnosis confirmed</strong> by positive immunoassay + differentiation assay or positive virological test (e.g., RNA PCR)</li>
      </ul>
    </div>

    <div class="section">
      <h2>Immediate Actions After Diagnosis</h2>
      <ul>
        <li>Refer urgently (within 7 days) to specialist HIV service</li>
        <li>Discuss transmission risks, prevention, partner notification, mental health, and ART adherence</li>
        <li>Do not initiate ART in primary care — manage by specialists</li>
      </ul>
    </div>

    <div class="section">
      <h2>Screening Recommendations</h2>
      <p>Offer opt-out HIV testing to:</p>
      <ul>
        <li>All patients in high-prevalence areas (diagnosis rate >2/1000)</li>
        <li>Pregnant women (routine antenatal screening)</li>
        <li>Anyone with HIV risk factor(s)</li>
        <li>Individuals attending sexual health, drug services, or TB clinics</li>
      </ul>
      <p>Repeat testing annually in ongoing risk.</p>
    </div>

    <div class="section">
      <h2>Acute HIV (Seropositive Illness)</h2>
      <ul>
        <li>Suspect in flu-like illness (fever, rash, pharyngitis, myalgia) 2–6 weeks post-exposure</li>
        <li>If high suspicion but negative/indeterminate test → test HIV RNA (PCR)</li>
        <li>Urgent referral — early ART may improve outcomes</li>
      </ul>
    </div>

    <div class="section">
      <h2>Referral & Admission Criteria</h2>
      <div class="card-grid">
        <div class="card">
          <h3>Refer Urgently (within 7 days)</h3>
          <ul>
            <li>Suspected acute HIV with symptoms</li>
            <li>Opportunistic infections (e.g., PCP, toxoplasmosis)</li>
            <li>CD4 < 200 cells/µL</li>
            <li>AIDS-defining illness (e.g., Kaposi’s sarcoma)</li>
            <li>ART toxicity or failure</li>
          </ul>
        </div>
        <div class="card">
          <h3>Admit Immediately</h3>
          <ul>
            <li>Hemodynamic instability</li>
            <li>Severe infection (e.g., PJP pneumonia, sepsis)</li>
            <li>Neurological compromise</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="section">
      <h2>Post-Exposure Prophylaxis (PEP)</h2>
      <ul>
        <li>Consider PEP if: recent (≤72 hrs) high-risk exposure (e.g., condomless sex with HIV+ partner, needle-stick)</li>
        <li>Start PEP within 72 hours (sooner = better)</li>
        <li>Typical regimen: tenofovir/emtricitabine + dolutegravir for 28 days</li>
        <li>Refer to sexual health or A&E for assessment and initiation</li>
      </ul>
      <div class="highlight-box">
        <strong>Note:</strong> PEP not needed after exposure to an HIV-positive partner with sustained undetectable viral load.
      </div>
    </div>

    <div class="section">
      <h2>Long-Term Management in Primary Care</h2>
      <ul>
        <li>Monitor for cardiovascular, renal, hepatic, and bone disease</li>
        <li>Vaccinations: annual flu, pneumococcal, HPV, hepatitis A/B</li>
        <li>Screen for depression, anxiety, and substance use</li>
        <li>Support sexual & reproductive health (including safe conception)</li>
        <li>Lifestyle advice: smoking cessation, alcohol, diet, exercise</li>
        <li>Coordinate with specialist HIV team — shared care encouraged</li>
      </ul>
    </div>

    <div class="section">
      <h2>Key Clinical Messages</h2>
      <div class="highlight-box">
        <ul>
          <li><strong>Early diagnosis saves lives</strong> — maintain a low threshold for testing.</li>
          <li><strong>All diagnosed cases require urgent specialist referral.</strong></li>
          <li><strong>PEP must start ≤72 hours post-exposure.</strong></li>
          <li><strong>Undetectable = Untransmittable (U=U)</strong> — reinforce with patients.</li>
          <li><strong>No cure, but ART enables near-normal life expectancy.</strong></li>
        </ul>
      </div>
    </div>

    <div class="footer">
      <p>Based on NICE CKS – HIV Infection and AIDS (March 2025)</p>
      <p>© Clarity Informatics Ltd (trading as Agilio Software Primary Care). Used under licence from NICE.</p>
      <p>For full guidance, visit <a href="https://cks.nice.org.uk" style="color: #1a539d;">cks.nice.org.uk</a></p>
    </div>
  </div>
</body>
</html>
```

---

### ✅ Features of This Webpage:
- **Clean, modern design** with a professional medical aesthetic.
- **Responsive layout** — works on desktop, tablet, and mobile.
- **Color-coded sections** for quick visual scanning.
- **Card-based UI** for key decision points (e.g., referral vs. admission).
- **Highlight box** for critical clinical messages.
- **Font and spacing** optimized for readability.
- **Embedded NICE CKS branding and revision date** for accuracy.

You can save this as an `.html` file and open it in any browser, or integrate it into an EMR portal, intranet, or clinical reference tool. Let me know if you'd like a printable PDF version or a dark mode variant.